Positive topline results from phase III SURPASS-1 trial of tirzepatide as treatment for type 2 diabetes

In trial of this dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, once-daily treatment with over 40 weeks resulted in an HbA1c reduction of 2.07% and reductions in body weight by 11% from baseline.

Source:

Biospace Inc.